Question 1

How do GLP-1 and GIP receptor agonists (tirzepatide, semaglutide) compare pharmacologically?

Accepted Answer

Semaglutide is a selective GLP-1 receptor agonist (weekly subcutaneous or daily oral), while tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist — sometimes called a "twincretin". GLP-1 receptor activation increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1R signalling. GIP receptor activation adds to the incretin effect on insulin secretion and also acts on adipose tissue GIP receptors to enhance fat storage/mobilisation — but the adipose GIP action in humans remains controversial. Pharmacokinetically, semaglutide (Ozempic 0.5–2 mg SC weekly) has a half-life of ~7 days due to albumin binding (C18 fatty acid); tirzepatide (2.5–15 mg SC weekly) has a half-life of ~5 days. In head-to-head SURMOUNT-5 trial, tirzepatide 10–15 mg produced 47% greater weight loss than semaglutide 2.4 mg at 72 weeks, primarily attributed to the additive dual-agonist mechanism and higher maximum dose. Both agents have cardiovascular benefit evidence (SUSTAIN-6/LEADER for semaglutide, SURPASS-CVOT for tirzepatide).

Question 2

What drug interactions are clinically important for levothyroxine?

Accepted Answer

Levothyroxine (T4) has numerous clinically significant drug interactions primarily mediated through four mechanisms: (1) Absorption interactions — drugs that bind levothyroxine in the gut and reduce absorption (take levothyroxine 4 hours away from these): calcium carbonate, ferrous sulphate/iron salts, aluminium/magnesium antacids, cholestyramine/colestipol, sucralfate, proton pump inhibitors (increase gastric pH, reducing T4 solubility), soybean formula, and fibre supplements. GLP-1 receptor agonists (delayed gastric emptying) may also reduce T4 absorption peak — separate administration recommended. (2) Metabolism induction — CYP450 inducers (rifampicin, carbamazepine, phenytoin) increase T4 metabolism, requiring higher doses. (3) Protein binding displacement — some drugs displace T4 from thyroxine-binding globulin (TBG) — furosemide, heparin, salicylates — transiently increasing free T4. (4) TBG concentration changes — oestrogens (OCP, HRT) increase TBG levels, requiring higher levothyroxine doses in hypothyroid women starting oestrogen therapy; androgens and glucocorticoids reduce TBG.

Question 3

What are the pharmacokinetic considerations for insulin formulations?

Accepted Answer

Insulin formulations differ substantially in their pharmacokinetics — onset, peak, and duration — which governs their clinical use. Rapid-acting analogues (insulin aspart, lispro, glulisine): onset 10–20 min, peak 1–3 hours, duration 3–5 hours — used for prandial coverage or insulin pumps; analogue modifications (e.g. aspart: B28 Asp substitution) reduce self-aggregation and accelerate absorption from subcutaneous depot. Ultra-rapid formulations (Fiasp, Lyumjev): additional excipients (niacinamide in Fiasp, citrate + EDTA in Lyumjev) further accelerate absorption for a more physiological postprandial response — onset ~5 min. Short-acting regular insulin: onset 30–60 min, peak 2–4 hours, duration 5–8 hours — used for IV insulin infusions (only soluble formulation safe IV). Intermediate-acting (NPH/isophane): onset 1–4 hours, duration 12–18 hours; variable absorption. Long-acting analogues (glargine U100, glargine U300, detemir, degludec): glargine forms microprecipitate at subcutaneous pH → slow dissolution; degludec forms fatty acid-albumin depot with ultra-long duration (~42 hours, lower variability). Insulin absorption is affected by injection site (abdomen fastest, thigh slowest), temperature, massage, lipohypertrophy, and physical activity.

Question 4

What are the bone safety considerations for drugs used in endocrinology?

Accepted Answer

Multiple drug classes used in endocrinology have clinically significant effects on bone metabolism. Glucocorticoids — the most important cause of drug-induced osteoporosis; suppress osteoblast activity, increase osteoclast lifespan, reduce intestinal calcium absorption, and increase renal calcium excretion; fracture risk increases significantly after >3 months of prednisolone ≥7.5 mg/day; prevention: calcium + vitamin D supplementation, and bisphosphonate (alendronate or risedronate) for patients on long-term systemic glucocorticoids. Aromatase inhibitors (letrozole, anastrozole, exemestane) — used in postmenopausal breast cancer; profound oestrogen deprivation accelerates bone loss; DEXA scan and bisphosphonate/denosumab therapy indicated for all patients on long-term AI therapy. Androgen deprivation therapy (LHRH agonists/antagonists in prostate cancer) — suppresses testosterone, causing significant bone loss (3–5% annual BMD reduction); bisphosphonates or denosumab prevent fractures. Thiazolidinediones (pioglitazone, rosiglitazone) — increase fracture risk in women by shifting mesenchymal stem cell differentiation from osteoblast to adipocyte. SSRIs — serotonin receptors on osteoblasts; SSRI use associated with reduced BMD and increased fracture risk.

Question 5

What is SGLT2 inhibitor pharmacology and what are the key safety signals?

Accepted Answer

SGLT2 (sodium-glucose co-transporter 2) inhibitors — empagliflozin (Jardiance), dapagliflozin (Forxiga/Farxiga), canagliflozin (Invokana) — reduce blood glucose by blocking the SGLT2 transporter in the proximal renal tubule, preventing glucose reabsorption and causing glycosuria. This insulin-independent mechanism provides additive glucose-lowering to any background therapy. Beyond glucose lowering, SGLT2i have proven cardiovascular and renal benefits: empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS/CREDENCE), and dapagliflozin (DECLARE-TIMI 58/DAPA-CKD/DAPA-HF) all showed significant reductions in heart failure hospitalisation, cardiovascular death, and renal endpoints — even in patients without diabetes. Key safety signals: (1) Genital mycotic infections — predictable consequence of glycosuria; more common in women (5–15%) and uncircumcised men; (2) Euglycaemic DKA — rare but serious; ketogenesis enhanced by glucagon rise and reduced insulin; most cases in Type 1 diabetes or perioperatively — withhold SGLT2i 3–4 days before surgery; (3) Fournier gangrene — rare necrotising fasciitis of perineum; FDA boxed warning; (4) Urinary tract infections; (5) Amputations — canagliflozin only, mechanism unknown; (6) Bone fractures — canagliflozin only; (7) Acute kidney injury — volume depletion, especially with diuretics/NSAIDs.

ENDO Annual Meeting 2027 — Endocrine Society

About ENDO 2027

2027 Programme Highlights

Incretin Pharmacology Update

SGLT2i Beyond Diabetes

Thyroid Drug Interactions

Insulin Formulation Innovation

Bone Safety of Endocrine Drugs

Pharmacogenomics in Endocrinology

Frequently Asked Questions

Related Content